The European Medicines Agency (EMA) today recommended the AstraZeneca-Oxford vaccine for emergency use in European Union (EU) countries, which came with more details about efficacy, which is about 60%, with the vaccine showing good impact against severe disease.The approval shed more light on findings from phase 3 clinical trials in the United Kingdom, Brazil, and South Africa and comes amid a row between EU officials and the company over supply contracts, which followed an announcement from the company that its supply would be less than expected.Questions on efficacy in seniors, against variantThe United Kingdom was the first country to green light the AstraZeneca-Oxford vaccine, clearing it for emergency use on Dec 30 based on interim